ZIOPHARM Oncology (NASDAQ:ZIOP)

CAPS Rating: 3 out of 5

ZIOP News and Commentary

Caps

How do you think ZIOP will perform against the market?

Add Stock to CAPS Watchlist

All Players

122 Outperform
16 Underperform
 

All-Star Players

15 Outperform
9 Underperform
 

Wall Street

6 Outperform
2 Underperform
 

Top ZIOP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mavrant (< 20)
Submitted June 02, 2011

possible new technology

zzlangerhans (99.85)
Submitted November 14, 2014

Ziopharm is up a decent chunk today, icing on the cake for anyone who found the stub tasty at October lows under 2.5. Nevertheless, I don't see this upswing carrying on past the company's presentations at AACR at the beginning of December. It seems… More

ZIOP VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ZIOP.

Recs

0
Member Avatar sk2129 (33.28) Submitted: 1/14/2016 2:06:37 PM : Outperform Start Price: $6.16 ZIOP Score: -71.22

baker bros.

Recs

0
Member Avatar Hendrickson71 (< 20) Submitted: 12/7/2015 1:49:22 PM : Underperform Start Price: $10.32 ZIOP Score: +88.12

There is a small chance that it will bounce, but I don't see decent protection from management's side. Probably 8s soon.

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 11/14/2014 4:04:41 PM : Underperform Start Price: $3.70 ZIOP Score: +18.08

Ziopharm is up a decent chunk today, icing on the cake for anyone who found the stub tasty at October lows under 2.5. Nevertheless, I don't see this upswing carrying on past the company's presentations at AACR at the beginning of December. It seems all Ziopharm had to do was make noise about CAR-T to tack on 40M in market cap, but it will soon become apparent that their efforts are very preliminary and they are far behind Kite, Juno, and Novartis among others. I expect the updates on Ad-RTS-IL-12 to be immaterial as well. Meanwhile, the company seems to be brushing MATISSE under the rug, as a promised interim OS analysis has failed to materialize. Ziopharm mutters something about the OS data being presented at a meeting in 2015 in their latest 10Q. Darinaparsin? The phase I trial of the oral formulation is fully enrolled, same as it was six months ago. Don't ask about indibulin. The company doesn't mention it even though it is still supposedly in development for breast cancer.

I know no one cares anymore about Ziopharm's small molecule platform. But the fact that they still find it necessary to obfuscate the failures rather than simply concede defeat in that area and move forward is an indication that management simply cannot be trusted. The company is promotional and cash is running low, which tells me that anyone buying into a run-up in the stock is going to get burned.

Leaderboard

Find the members with the highest scoring picks in ZIOP.

Score Leader

EdFromOhio

EdFromOhio (42.01) Score: +424.12

The Score Leader is the player with the highest score across all their picks in ZIOP.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
AGCAPS1 < 20 1/26/2011 Underperform 1Y $5.98 -30.27% +105.52% +135.78 1 Comment
dpgardne < 20 10/10/2012 Underperform 5Y $5.02 -16.93% +85.03% +101.96 0 Comment
bluebare 29.69 11/14/2012 Underperform 5Y $4.47 -6.71% +93.03% +99.74 0 Comment
GreenAB 97.29 3/5/2015 Underperform 5Y $13.94 -70.08% +26.62% +96.70 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 70.48 4/5/2013 Outperform 5Y $1.56 +168.17% +72.88% +95.29 0 Comment
Hendrickson71 < 20 12/7/2015 Underperform 3W $10.32 -59.59% +28.53% +88.12 1 Comment
sjinvestor 44.14 1/16/2015 Underperform 3Y $8.11 -48.58% +34.22% +82.80 0 Comment
shonny2 < 20 5/22/2013 Outperform 5Y $1.82 +128.62% +59.12% +69.50 0 Comment
KidJones 29.90 1/13/2015 Underperform 5Y $5.99 -30.38% +30.70% +61.08 0 Comment
VeryShiny < 20 4/9/2013 Outperform 3M $1.83 +127.87% +70.25% +57.62 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPiperJaff 85.03 3/27/2013 Underperform NS $1.77 +135.59% +71.83% -63.77 0 Comment
TrackCanaccord < 20 3/26/2012 Outperform NS $5.20 -19.81% +89.68% -109.48 0 Comment
trackglobalhunte < 20 12/15/2011 Outperform NS $4.35 -4.14% +116.84% -120.98 0 Comment
TrackCollinsStew 72.70 11/22/2011 Outperform NS $4.37 -4.58% +123.43% -128.01 0 Comment
TrackJimCramer 85.09 7/28/2011 Underperform 3W $5.47 -23.77% +104.87% +128.63 0 Comment
TrackBarclaysCap 90.60 2/23/2011 Outperform NS $5.85 -28.72% +104.05% -132.77 0 Comment
TrackZacks < 20 12/30/2010 Underperform 3M $4.77 -1.68% +9.90% +11.57 11/9/2012 @ $4.69 1 Comment
TrackDawsonJames < 20 8/2/2010 Outperform NS $3.81 +9.45% +138.22% -128.77 0 Comment
TrackRodmanRen < 20 6/23/2010 Outperform NS $3.50 +19.14% +143.32% -124.18 0 Comment

Featured Broker Partners